BDB 018
Alternative Names: BDB-018Latest Information Update: 28 Jul 2024
At a glance
- Originator Seven and Eight Biopharmaceuticals
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV)
- 01 Jun 2023 Seven and Eight Biopharmaceuticals and Eikon Therapeutics enters into a licensing agreement to develop and commercialize TLR7/8 agonists Worldwide